NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...

Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

Gregory M. Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals plc (NASDAQ:CNTA), a $2.16 billion market cap ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock ...

Hypervitaminosis A can be diagnosed using blood tests to check your vitamin A levels. Most people improve simply by decreasing their intake of vitamin A. Hypervitaminosis A, or vitamin A toxicity ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Unveiling the Future of Chronic Insomnia treatment – DelveInsight's latest report explores epidemiological insights and market opportunities spanning the 7MM. LAS VEGAS , NV, UNITED STATES, January 31 ...

Access to the live webcasts of these events, as well as archived recordings, will be available under the "Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals ...

Evan Coleman is an Updates Editor on the Credit Cards and Travel Rewards team at Forbes Advisor, showcasing his interest in personal finance and love of travel. He has written for a variety of ...